Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

World J Gastroenterol · 2018 · PMC6158485 · PMID 30271080

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

BIOLOGICAL PARAMETERS Serum and plasma proteins Although plasma biomarkers are the best candidates for evaluating sorafenib efficacy, only the SHARP trial produced results with borderline significance[ 4 ].

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.